Results 211 to 220 of about 250,617 (262)
An NK-like CAR T cell transition in CAR T cell dysfunction
Cell, 2021 Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer, we establish a robust model of continuous antigen ...
Shelley Berger +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
New England Journal of Medicine, 2017
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed ...
Eric, Tran, Dan L, Longo, Walter J, Urba
openaire +2 more sources
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed ...
Eric, Tran, Dan L, Longo, Walter J, Urba
openaire +2 more sources
2022
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
Onkologische Pflege, 2020
Die CAR-T-Zell-Therapie ist eine Immuntherapie, bei der körpereigene T-Zellen entnommen, gentechnisch verändert und dem Körper anschließend wieder zugeführt werden, um dann die Tumoroberfläche zu erkennen und die Tumorzelle zu zerstören. Häufig auftretende Nebenwirkungen sind Zytokinsturm und Neurotoxizität, die eine engmaschige Überwachung der ...
Barbara Huber, Chrissoula Kiote-Schmidt
openaire +1 more source
Die CAR-T-Zell-Therapie ist eine Immuntherapie, bei der körpereigene T-Zellen entnommen, gentechnisch verändert und dem Körper anschließend wieder zugeführt werden, um dann die Tumoroberfläche zu erkennen und die Tumorzelle zu zerstören. Häufig auftretende Nebenwirkungen sind Zytokinsturm und Neurotoxizität, die eine engmaschige Überwachung der ...
Barbara Huber, Chrissoula Kiote-Schmidt
openaire +1 more source